HIVandHepatitis.com coverage of the 50th European Association for the Study of the Liver International Liver Congress (EASL 2015) in Vienna, April 22-26, 2015.
Conference highlights include interferon-free hepatitis C treatment for people with advanced disease, experimental HCV antivirals, hepatitis B and delta, and management of liver disease complications.
HIVandHepatitis.com coverage of the 2015 Conference on Retroviruses and Opportunistic infections (CROI 2015), February 23-26, 2015, in Seattle.
Conference highlights include PrEP and HIV treatment as prevention, hepatitis C treatment for HIV/HCV coinfected people, new antiretroviral drugs, HIV cure research, HIV-related conditions, TB, Ebola virus, and access to care.
A fixed-dose combination pill containing tenofovir alafenamide (TAF) worked as well in a Phase 3 trial as the current Truvada pill containing the older tenofovir disoproxil fumarate (TDF) -- which is used for both HIV treatment and pre-exposure prophylaxis or PrEP -- but causes less kidney and bone toxicity, according to an announcement this week from Gilead Sciences.
One-third of people who started combination antiretroviral therapy (ART) many years ago using first-generation protease inhibitors did not achieve complete immunological recovery with normal CD4 T-cell counts despite good viral suppression, according to a French study presented at the recent 8th International AIDS Society Conference on HIV Pathogenesis, Treatment, and Prevention in Vancouver.